摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-chloro-2-[(1,4-trans)-1,4-dimethyl-4-hydroxycyclohexylcarbonyl]-6-(4-ethylpiperazin-1-yl) benzimidazole

中文名称
——
中文别名
——
英文名称
5-chloro-2-[(1,4-trans)-1,4-dimethyl-4-hydroxycyclohexylcarbonyl]-6-(4-ethylpiperazin-1-yl) benzimidazole
英文别名
2-Cyclohexylcarbonylbenzimidazole, 7c;[6-chloro-5-(4-ethylpiperazin-1-yl)-1H-benzimidazol-2-yl]-(4-hydroxy-1,4-dimethylcyclohexyl)methanone
5-chloro-2-[(1,4-trans)-1,4-dimethyl-4-hydroxycyclohexylcarbonyl]-6-(4-ethylpiperazin-1-yl) benzimidazole化学式
CAS
——
化学式
C22H31ClN4O2
mdl
——
分子量
418.967
InChiKey
NXSFKUCSWRJBEE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    29
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    72.5
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    6-chloro-2-[(1,4-trans)-1,4-dimethyl-4-hydroxycyclohexylcarbonyl]-5-(4-ethylpiperazin-1-yl)-1-[2-(trimethylsilyl)ethoxymethyl]benzimidazole 、 5-chloro-2-[(1,4-trans)-1,4-dimethyl-4-hydroxycyclohexylcarbonyl]-6-(4-ethylpiperazin-1-yl)-1-[2-(trimethylsilyl)ethoxymethyl]benzimidazole 在 四丁基氟化铵 作用下, 以 四氢呋喃 为溶剂, 反应 4.0h, 生成 5-chloro-2-[(1,4-trans)-1,4-dimethyl-4-hydroxycyclohexylcarbonyl]-6-(4-ethylpiperazin-1-yl) benzimidazole
    参考文献:
    名称:
    Benzimidazole derivatives
    摘要:
    这项发明提供了一些化合物,它们由一般式[I]1表示,其中X代表氢或卤素;B代表卤素、氰基或者可选的含氟低碳基;D代表一个3-10个成员的脂肪氮杂环基团;R3、R4和R5可能相同也可能不同,每个代表氢、可选的取代基的低碳基等;a为0或1。这些化合物表现出高亲和力对于痛觉受体,并抑制痛觉素的作用,因此可用作镇痛剂、抗肥胖剂、改善脑功能的药物、治疗阿尔茨海默病和痴呆症的药物、以及治疗精神分裂症、神经退行性疾病、抑郁症、尿崩症、多尿症、低血压等的治疗剂。
    公开号:
    US20030236267A1
点击查看最新优质反应信息

文献信息

  • BENZIMIDAZOLE DERIVATIVES
    申请人:BANYU PHARMACEUTICAL CO., LTD.
    公开号:EP1505063A1
    公开(公告)日:2005-02-09
    This invention provides compounds which are represented by a general formula [I]    [in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3-10 membered aliphatic nitrogen-containing heterocyclic group; R3, R4 and R5 may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.
    本发明提供了通式[I]表示的化合物。 [其中,X 代表氢或卤素;B 代表卤素、氰基或任选由氟取代的低级烷基;D 代表 3-10 位脂肪族含氮杂环基团;R3、R4 和 R5 可以相同或不同,各自代表氢、任选具有取代基团的低级烷基等;a 为 0 或 1]。这些化合物对痛觉素受体具有高亲和力,从而抑制痛觉素的作用,可用作镇痛剂、抗镇静剂、改善脑功能的药物、治疗阿尔茨海默病和痴呆症的药物,以及精神分裂症、神经退行性疾病、抑郁症、糖尿病、多尿症、低血压等疾病的治疗药物。
  • US7125877B2
    申请人:——
    公开号:US7125877B2
    公开(公告)日:2006-10-24
  • [EN] TREATMENT OF URINARY CONDITIONS INCLUDING INCONTINENCE<br/>[FR] TRAITEMENT DE TROUBLES URINAIRES, Y COMPRIS L'INCONTINENCE
    申请人:PFIZER LTD
    公开号:WO2005117862A1
    公开(公告)日:2005-12-15
    The invention relates to the use of nociceptin receptor antagonists for the treatment of urinary conditions such as overactive bladder, urgency, urge incontinence, frequency, nocturia, stress incontinence and mixed urinary incontinence, in particular overactive bladder, urgency, urge incontinence, frequency, nocturia and/or mixed urinary incontinence. The invention also relates to methods of screening for compounds for the use in the treatment of urinary conditions such as overactive bladder, urgency, urge incontinence, frequency, nocturia, stress incontinence and mixed urinary incontinence, in particular overactive bladder, urgency, urge incontinence, frequency, nocturia and/or mixed urinary incontinence.
  • Benzimidazole derivatives
    申请人:——
    公开号:US20030236267A1
    公开(公告)日:2003-12-25
    This invention provides compounds which are represented by a general formula [I] 1 [in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3-10 membered aliphatic nitrogen-containing heterocyclic group; R 3 , R 4 and R 5 may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.
    这项发明提供了一些化合物,它们由一般式[I]1表示,其中X代表氢或卤素;B代表卤素、氰基或者可选的含氟低碳基;D代表一个3-10个成员的脂肪氮杂环基团;R3、R4和R5可能相同也可能不同,每个代表氢、可选的取代基的低碳基等;a为0或1。这些化合物表现出高亲和力对于痛觉受体,并抑制痛觉素的作用,因此可用作镇痛剂、抗肥胖剂、改善脑功能的药物、治疗阿尔茨海默病和痴呆症的药物、以及治疗精神分裂症、神经退行性疾病、抑郁症、尿崩症、多尿症、低血压等的治疗剂。
查看更多